Our Resources

DCTs offer an effective avenue for studying what are sometimes considered “taboo” therapeutic areas while respecting participants’ discretion.

Novotech, a leading biotech specialist CRO in the Asia-Pacific region, and virtual research organization (VRO) partner ObvioHealth have been selected as finalists for the Clinical Partnership of the Year Citeline Award by Informa Pharma Intelligence. ObvioHealth is Novotech’s preferred provider for virtual clinical trials in APAC, while Novotech is ObvioHealth’s preferred CRO in the region for hybrid and virtual trials.

NEW YORK, September 30, 2021 - ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of a first-of-its kind clinical trial in Australia, using a combination of in-home data collection methods that will reduce and in some cases eliminate the need for follow-up visits to clinics.

NEW YORK – August 17, 2021 - Inc. Magazine today ranked ObvioHealth, a leading global Virtual Research Organization (VRO), at No. 390 on its annual list of the nation’s fastest-growing private companies, confirming ObvioHealth’s impressive growth in the decentralized clinical trials (DCT) space.

ObvioHealth looks to grow expertise in deep tech. We immediately recognized that Singapore could fill this need. Here, we can tap into a rich ecosystem of health tech companies and talent.

ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies.

ObvioHealth, a global virtual research organization or VRO, today announced the launch of a hybrid clinical trial for the treatment of COVID-19, using an innovative study design with digital data capture to remotely monitor patient vitals.